Organization | Medanta - The Medicity

Medanta - The Medicity Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2012

NCT01484574

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Medanta, The Medicity, India

Active Ingredients

Drugs in Phase 4 Trials (2)

dapagliflozin (farxiga) (2 trials)

insulin glargine (toujeo) (2 trials)

Drugs in Phase 2 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Drugs in Other Trials (7)

bempedoic acid (NEXLETOL) (1 trial)

dulaglutide (trulicity) (1 trial)

empagliflozin (jardiance) (3 trials)

insulin degludec (tresiba) (1 trial)

linagliptin (tradjenta) (2 trials)

semaglutide (Ozempic) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Ischemia (Phase 2)

Thromboangiitis Obliterans (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 10